Millstone Evans Group, LLC Ligand Pharmaceuticals Inc Transaction History
Millstone Evans Group, LLC
- $147 Billion
- Q4 2024
A detailed history of Millstone Evans Group, LLC transactions in Ligand Pharmaceuticals Inc stock. As of the latest transaction made, Millstone Evans Group, LLC holds 133 shares of LGND stock, worth $14,047. This represents 0.01% of its overall portfolio holdings.
Number of Shares
133Holding current value
$14,047% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding LGND
# of Institutions
276Shares Held
18.5MCall Options Held
30.8KPut Options Held
5.2K-
Black Rock Inc. New York, NY2.87MShares$303 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.09MShares$220 Million0.0% of portfolio
-
Janus Henderson Group PLC London, X01.02MShares$107 Million0.06% of portfolio
-
Macquarie Group LTD Australia, C3884KShares$93.4 Million0.11% of portfolio
-
State Street Corp Boston, MA744KShares$78.5 Million0.0% of portfolio
About LIGAND PHARMACEUTICALS INC
- Ticker LGND
- Exchange OTC
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 16,882,800
- Market Cap $1.78B
- Description
- Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...